Royal Marsden Announces Retifanlimab Approval Following Dr Sheela Rao-Led Trial
Sheela Rao/royalmarsden.nhs.uk

Royal Marsden Announces Retifanlimab Approval Following Dr Sheela Rao-Led Trial

The Royal Marsden NHS Foundation Trust shared on LinkedIn:

“NEWS: Immunotherapy treatment in Royal Marsden-led clinical trial receives the Medicines and Healthcare products Regulatory Agency (MHRA) and NICE – National Institute for Health and Care Excellence approval.

The Royal Marsden welcomes the decision by MHRA and NICE to approve use of retifanlimab for treating the most common type of anal cancer.

The immunotherapy has been approved for use in combination with chemotherapies carboplatin and paclitaxel for the first-line treatment of inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).

The approval was supported by positive results from the phase three POD1UM-303/InterAACT2 trial, led by The Royal Marsden.

Dr Sheela Rao, Consultant Medical Oncologist at The Royal Marsden, and global chief investigator of the POD1UM-303/InterAACT2 study, said:

‘This trial demonstrates it is possible to conduct research in rare cancers with global collaboration and commitment.

I am delighted to see this treatment become available through the NHS and I would like to thank everyone; patients, colleagues and teams around the world, who have contributed to the study and helped make this result possible.’

Read the full story”

You may also be interested in:

Royal Marsden Announces Retifanlimab Approval Following Dr Sheela Rao-Led Trial